Reproducibility in serial C-reactive protein and interleukin-6 measurements in post-myocardial infarction patients: Results from the AIRGENE study

Clinical Chemistry

Volumn 56, Issue 5, 2010, Pages 861-864

  Karakas, Mahir ^a   Baumert, Jens ^b   Greven, Sonja ^c   Rückerl, Regina ^b   Peters, Annette ^b   Koenig, Wolfgang ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL PRACTICE; CONTROLLED STUDY; DRESSLER SYNDROME; FEMALE; HUMAN; MALE; MEASUREMENT; PROTEIN BLOOD LEVEL; RELIABILITY; REPRODUCIBILITY;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; REPRODUCIBILITY OF RESULTS;

EID: 77951757953     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.143719     Document Type: Article

References (19)

1. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007;27:15-26. (Pubitemid 46360377)
2. Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-140
3. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007;297:611-619 (Pubitemid 46257283)
4. Wilson PW, Pencina M, Jacques P, Selhub J, D'Agostino R Sr, O'Donnell CJ. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008;1:92-97
5. Ridker PM, Danielson E, Fonseca F, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207
6. Le JM, Vilcek J. Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 1989;61:588-602.
7. Danesh J, Kaptoge S, Mann A, Sarwar N, Wood A, Angleman SB, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008;5:e78. (Pubitemid 351649259)
8. Rudez G, Meijer P, Spronk HM, Leebeek FW, ten Cate H, Kluft C, de Maat MP. Biological variation in inflammatory and hemostatic markers. J Thromb Haemost 2009;7:1247-1255
9. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001;47:444-450 (Pubitemid 32222458)
10. Peters A, Schneider A, Greven S, Bellander T, Forastiere F, Ibald-Mulli A, et al. Air pollution and inflammatory response in myocardial infarction survivors: gene-environment interactions in a high-risk group. Inhal Toxicol 2007;19(Suppl 1):161-175 (Pubitemid 47450700)
11. Ljungman P, Bellander T, Nyberg F, Lampa E, Jacquemin B, Kolz M, et al. DNA variants, plasma levels and variability of interleukin-6 in myocardial infarction survivors: results from the AIRGENE study. Thromb Res 2009;124:57-64.
12. Kolz M, Koenig W, Müller M, Andreani M, Greven S, Illig T, et al. DNA variants, plasma levels and variability of C-reactive protein in myocardial infarction survivors: results from the AIRGENE study. Eur Heart J 2008;29:1250-1258
13. Fleiss JL. The design and analysis of clinical experiments. New York: Wiley; 1986.
14. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999;8:135-160 (Pubitemid 29425900)
15. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409-437
16. Summary of the second report of the National Cholesterol Educational Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023
17. Glynn RJ, MacFadyen JG, Ridker PM. Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER study. Clin Chem 2009;55:305-312
18. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E, for the Cholesterol and Recurrent Events (CARE) investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230-235
19. Rückerl R, Peters A, Khuseyinova N, Andreani M, Koenig W, Meisinger C, et al. Determinants of the acute-phase protein C-reactive protein in myocardial infarction survivors: the role of comorbidities and environmental factors. Clin Chem 2009;55:322-335